DexCom Statistics
Total Valuation
DexCom has a market cap or net worth of $51.69 billion. The enterprise value is $51.88 billion.
| Market Cap | 51.69B |
| Enterprise Value | 51.88B |
Important Dates
The last earnings date was Thursday, April 25, 2024, after market close.
| Earnings Date | Apr 25, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
DexCom has 397.68 million shares outstanding. The number of shares has decreased by -0.43% in one year.
| Shares Outstanding | 397.68M |
| Shares Change (YoY) | -0.43% |
| Shares Change (QoQ) | -0.10% |
| Owned by Insiders (%) | 0.36% |
| Owned by Institutions (%) | 97.07% |
| Float | 393.85M |
Valuation Ratios
The trailing PE ratio is 85.30 and the forward PE ratio is 69.76. DexCom's PEG ratio is 2.53.
| PE Ratio | 85.30 |
| Forward PE | 69.76 |
| PS Ratio | 13.74 |
| Forward PS | 11.36 |
| PB Ratio | 23.25 |
| P/FCF Ratio | 89.53 |
| PEG Ratio | 2.53 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 52.35, with an EV/FCF ratio of 88.90.
| EV / Earnings | 81.14 |
| EV / Sales | 13.64 |
| EV / EBITDA | 52.35 |
| EV / EBIT | 65.33 |
| EV / FCF | 88.90 |
Financial Position
The company has a current ratio of 2.90, with a Debt / Equity ratio of 1.13.
| Current Ratio | 2.90 |
| Quick Ratio | 2.43 |
| Debt / Equity | 1.13 |
| Debt / EBITDA | 2.56 |
| Debt / FCF | 4.34 |
| Interest Coverage | 50.58 |
Financial Efficiency
Return on equity (ROE) is 29.40% and return on invested capital (ROIC) is 11.20%.
| Return on Equity (ROE) | 29.40% |
| Return on Assets (ROA) | 9.80% |
| Return on Capital (ROIC) | 11.20% |
| Revenue Per Employee | $396,021 |
| Profits Per Employee | $66,594 |
| Employee Count | 9,600 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.96 |
Taxes
In the past 12 months, DexCom has paid $139.10 million in taxes.
| Income Tax | 139.10M |
| Effective Tax Rate | 17.87% |
Stock Price Statistics
The stock price has increased by +10.77% in the last 52 weeks. The beta is 1.22, so DexCom's price volatility has been higher than the market average.
| Beta (1Y) | 1.22 |
| 52-Week Price Change | +10.77% |
| 50-Day Moving Average | 133.19 |
| 200-Day Moving Average | 114.88 |
| Relative Strength Index (RSI) | 52.22 |
| Average Volume (30 Days) | 2,925,872 |
Short Selling Information
The latest short interest is 11.10 million, so 2.79% of the outstanding shares have been sold short.
| Short Interest | 11.10M |
| Short Previous Month | 11.77M |
| Short % of Shares Out | 2.79% |
| Short % of Float | 2.82% |
| Short Ratio (days to cover) | 3.84 |
Income Statement
In the last 12 months, DexCom had revenue of $3.80 billion and earned $639.30 million in profits. Earnings per share was $1.54.
| Revenue | 3.80B |
| Gross Profit | 2.39B |
| Operating Income | 651.60M |
| Pretax Income | 778.40M |
| Net Income | 639.30M |
| EBITDA | 991.00M |
| EBIT | 794.10M |
| Earnings Per Share (EPS) | $1.54 |
Balance Sheet
The company has $2.90 billion in cash and $2.53 billion in debt, giving a net cash position of $364.50 million or $0.92 per share.
| Cash & Cash Equivalents | 2.90B |
| Total Debt | 2.53B |
| Net Cash | 364.50M |
| Net Cash Per Share | $0.92 |
| Equity / Book Value | 2.25B |
| Book Value Per Share | 5.65 |
| Working Capital | 3.03B |
Cash Flow
In the last 12 months, operating cash flow was $802.30 million and capital expenditures -$218.80 million, giving a free cash flow of $583.50 million.
| Operating Cash Flow | 802.30M |
| Capital Expenditures | -218.80M |
| Free Cash Flow | 583.50M |
| FCF Per Share | $1.50 |
Margins
Gross margin is 62.82%, with operating and profit margins of 17.14% and 16.82%.
| Gross Margin | 62.82% |
| Operating Margin | 17.14% |
| Pretax Margin | 20.47% |
| Profit Margin | 16.82% |
| EBITDA Margin | 26.07% |
| EBIT Margin | 20.89% |
| FCF Margin | 15.35% |
Dividends & Yields
DexCom does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.43% |
| Shareholder Yield | 0.43% |
| Earnings Yield | 1.22% |
| FCF Yield | 1.12% |
Analyst Forecast
The average price target for DexCom is $141.67, which is 8.99% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $141.67 |
| Price Target Difference | 8.99% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 17.38% |
| EPS Growth Forecast (5Y) | 25.37% |
Stock Splits
The last stock split was on June 13, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Jun 13, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
DexCom has an Altman Z-Score of 9.2 and a Piotroski F-Score of 6.
| Altman Z-Score | 9.2 |
| Piotroski F-Score | 6 |